Results 241 to 250 of about 17,710 (254)

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet, The, 2017
Andrew Blauvelt, Marjolein de Bruin-Weller, Melinda Gooderham   +2 more
exaly  

Dupilumab’s duplicity

Journal of the American Academy of Dermatology
openaire   +2 more sources

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

Lancet, The, 2016
D Thaçi, Lisa A Beck, Thomas Bieber
exaly  

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

New England Journal of Medicine, 2018
Ian D Pavord, Jorge F Maspero, Sally E Wenzel   +2 more
exaly  

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Lancet, The, 2022
exaly  

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

New England Journal of Medicine, 2014
Lisa A Beck, D Thaçi, Jennifer Davidson Hamilton   +2 more
exaly  

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

New England Journal of Medicine, 2018
Klaus F Rabe, Parameswaran Nair, Guy G Brusselle   +2 more
exaly  

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Lancet, The, 2019
Claus Bachert, Martin Desrosiers, Peter Hellings   +2 more
exaly  

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

New England Journal of Medicine, 2013
Sally E Wenzel, Allen Radin
exaly  

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

Lancet, The, 2016
Sally E Wenzel, Mario Castro, Jonathan Corren   +2 more
exaly